Navigation Links
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
Date:1/22/2014

New Rochelle, NY, January 22, 2014Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cancer Biotherapy and Radiopharmaceuticals website.

"High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines" describes a statistically significant improvement in survival for patients who received IL2 plus tumor cell-based immunotherapy. Authors Robert Dillman, Carol DePriest and Stephanie McClure, Hoag Institute for Research and Education, Hoag Family Cancer Institute, and Cancer Biotherapy Research Group, Newport Beach, CA, found that administration of immunotherapy after IL2 treatment resulted in longer patient survival than if individuals were vaccinated before receiving IL2.

"This is an important addition to the literature on IL2 treatment for metastatic melanoma demonstrating that personalized vaccine therapy contributed to an increased survival rate," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Page: 1

Related biology news :

1. How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy?
2. A cost-effective way toward personalized cancer drugs
3. Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
4. "GenoVive is changing the face of personalized health by continuing research efforts with Harvard."
5. Cancer research implies future for personalized medicine, reduction in animal testing
6. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
7. Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market
8. Personalized health care will revolutionize 21st century medicine, says NJIT professor
9. Personalized medicine eliminates need for drug in 2 children
10. Report from the front lines of personalized reproductive medicine revolution
11. BodyMedia & FitOrbit Up the Ante in Personalized Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
(Date:5/21/2019)... ... May 21, 2019 , ... If a genetically ... How can we tell it apart from the millions of microorganisms that exist ... research team, including Eric Young , assistant professor of chemical engineering at ...
(Date:5/21/2019)... ... May 20, 2019 , ... Dr. David Greene , Founder and ... Stem Cell Therapy: Biotechnology to the Rescue, was produced by Award Winning filmmaker Dr. ... interviewed in regards to the safety of the procedures along with the potential for ...
(Date:5/16/2019)... ... ... In a FDA-contracted Standard Coordinating Body Workshop held at the National Institute ... founder and director James L. Sherley, M.D., Ph.D. predicted a sea change in ... Many of the gathered participants dismissed this idea. Few argued against the importance ...
Breaking Biology News(10 mins):
(Date:4/15/2019)... (PRWEB) , ... April 15, 2019 , ... ... has completed construction of a $2 million bench plant expansion to increase production ... important step in the design and construction of Sirrus’ full-scale production facility, which ...
(Date:4/10/2019)... ... April 10, 2019 , ... ... locked into multiple agreements to help companies advance their innovations to clinical ... ranging from synthetic biology companies that are gene editing therapeutic cells for ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM ... capacity of life sciences organizations to accelerate innovation and maximize productivity, announces that ... the past 12 months. , USDM’s Cloud Assurance is a managed ...
(Date:4/9/2019)... ... , ... The American Society of Gene & Cell Therapy (ASGCT) ... new addition to the presidential line of succession, at the 22nd Annual Meeting ... team for a three-year term (2019-2021). , All five incoming members of the ...
Breaking Biology Technology: